Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified talc; glyceryl monostearate; iron oxide yellow; hypromellose; microcrystalline cellulose; methacrylic acid copolymer; synthetic paraffin; iron oxide red; triethyl citrate; macrogol 6000; polysorbate 80; crospovidone; titanium dioxide; magnesium stearate; hyprolose; sodium stearylfumarate; maize starch; sucrose - nexium is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with nexium iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified talc; glyceryl monostearate; iron oxide yellow; hypromellose; microcrystalline cellulose; methacrylic acid copolymer; synthetic paraffin; iron oxide red; triethyl citrate; macrogol 6000; polysorbate 80; crospovidone; titanium dioxide; magnesium stearate; hyprolose; sodium stearylfumarate; maize starch; sucrose - esopreze is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with esopreze iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; crospovidone; purified talc; iron oxide yellow; sodium stearylfumarate; synthetic paraffin; methacrylic acid copolymer; hypromellose; hyprolose; triethyl citrate; iron oxide red; magnesium stearate; polysorbate 80; glyceryl monostearate; titanium dioxide; macrogol 6000; maize starch; sucrose - healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified talc; glyceryl monostearate; iron oxide yellow; hypromellose; microcrystalline cellulose; methacrylic acid copolymer; synthetic paraffin; iron oxide red; triethyl citrate; macrogol 6000; polysorbate 80; crospovidone; titanium dioxide; magnesium stearate; hyprolose; sodium stearylfumarate; maize starch; sucrose - refexxin is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified talc; glyceryl monostearate; iron oxide yellow; hypromellose; microcrystalline cellulose; methacrylic acid copolymer; synthetic paraffin; iron oxide red; triethyl citrate; macrogol 6000; polysorbate 80; crospovidone; titanium dioxide; magnesium stearate; hyprolose; sodium stearylfumarate; maize starch; sucrose - axagon is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - capsule, hard - excipient ingredients: hypromellose; propylene glycol; indigo carmine aluminium lake; carmine; magnesium stearate; gelatin; purified talc; methacrylic acid copolymer; titanium dioxide; erythrosine; iron oxide yellow; indigo carmine; povidone; shellac; triethyl citrate; sodium hydroxide; allura red ac; glyceryl monostearate; polysorbate 80; hyprolose; sucrose; hydrolysed maize starch - nexium 24hr once daily dosing is indicated for the symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux disease (gord).

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 11.1 mg (equivalent: esomeprazole, qty 10 mg) - granules, enteric-coated - excipient ingredients: crospovidone; xanthan gum; polysorbate 80; hyprolose; triethyl citrate; hypromellose; iron oxide yellow; magnesium stearate; citric acid; purified talc; glucose; glyceryl monostearate; methacrylic acid copolymer; maize starch; sucrose; hydrolysed maize starch - nexium is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with nexium iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 44.5 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: iron oxide red; microcrystalline cellulose; polysorbate 80; triethyl citrate; synthetic paraffin; titanium dioxide; crospovidone; hypromellose; purified talc; glyceryl monostearate; methacrylic acid copolymer; magnesium stearate; hyprolose; sodium stearylfumarate; macrogol 6000; maize starch; sucrose - nexium is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with nexium iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 44.5 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: iron oxide red; microcrystalline cellulose; polysorbate 80; triethyl citrate; synthetic paraffin; titanium dioxide; crospovidone; hypromellose; purified talc; glyceryl monostearate; methacrylic acid copolymer; magnesium stearate; hyprolose; sodium stearylfumarate; macrogol 6000; maize starch; sucrose - esopreze is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with esopreze iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers. patients are considered to be at risk due to their age (≥ 60) and/or d